Carnitine deficiency: genes and variants
Explore variant evidence for Carnitine deficiency across 1 analyzed protein (SLC22A5). Linked ClinVar records include 82 pathogenic or likely pathogenic variants, 292 variants of uncertain significance and 59 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Carnitine deficiency
SLC22A5: Organic cation/carnitine transporter 2
It imports carnitine into cells and reabsorbs filtered carnitine in the kidney, maintaining the stores required for mitochondrial long-chain fatty-acid oxidation. Biallelic loss-of-function variants cause primary carnitine deficiency with hypoketotic hypoglycemia, skeletal weakness, or cardiomyopathy.
82 ClinVar pathogenic / likely pathogenic and 351 uncertain variants in SLC22A5 have source records linked to Carnitine deficiency. Association strength is not clinical gene validity.
Where Carnitine deficiency variants cluster
- SLC22A5 Cytoplasmic (positions 1–20): 10 of 81 ClinVar pathogenic / likely pathogenic variants, 3.4× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Carnitine deficiency
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SLC22A5 Y211H | 211 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R471L | 471 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R471P | 471 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 G15W | 15 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P46S | 46 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R169Q | 169 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R169W | 169 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 Y211C | 211 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R227H | 227 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R471S | 471 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R471C | 471 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 M1T | 1 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 C113Y | 113 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC22A5 G152D | 152 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R227C | 227 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P266L | 266 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 S26N | 26 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 Y358N | 358 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 Y358C | 358 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P478L | 478 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P143L | 143 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 G234R | 234 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 L273P | 273 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R399Q | 399 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R399W | 399 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 M433T | 433 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 G462D | 462 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 L507S | 507 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R19P | 19 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 F230L | 230 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P247R | 247 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 T264R | 264 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 A301D | 301 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 A442I | 442 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 P455R | 455 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC22A5 Y387H | 387 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC22A5 R227G | 227 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 R282P | 282 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 R282G | 282 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 G15R | 15 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 S26R | 26 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 R169P | 169 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 Q207R | 207 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 R227L | 227 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 R227S | 227 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 W14R | 14 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 S26G | 26 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 S28R | 28 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 P46A | 46 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC22A5 C50Y | 50 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC22A5 P266R | 266 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 W283R | 283 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 M1V | 1 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 G12R | 12 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 P31L | 31 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 A44V | 44 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC22A5 R83C | 83 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC22A5 G168D | 168 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| SLC22A5 Q207H | 207 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC22A5 L263R | 263 | Transmembrane | Pathogenic / likely pathogenic (★) |
Showing 60 of 82.
Uncertain variants prioritized for review in Carnitine deficiency
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| SLC22A5 G15E | 15 | Cytoplasmic | Conflicting reports (★) | +7: 4 other pathogenic changes within 3 positions; G15R at the same position is pathogenic; seen in 4.8e-06 of gnomAD DNA copies; REVEL 0.874 |
| SLC22A5 R83P | 83 | Extracellular | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; R83C at the same position is pathogenic; seen in 7e-07 of gnomAD DNA copies; REVEL 0.818 |
| SLC22A5 G12D | 12 | Cytoplasmic | Uncertain (★★) | +7: 4 other pathogenic changes within 3 positions; G12R at the same position is pathogenic; seen in 2.7e-06 of gnomAD DNA copies; REVEL 0.940 |
| SLC22A5 C50W | 50 | Extracellular | Uncertain (★★) | +7: in a 3D region that tolerates change poorly (1R); C50Y at the same position is pathogenic; seen in 6.9e-07 of gnomAD DNA copies; REVEL 0.836 |
| SLC22A5 A214V | 214 | Transmembrane | Conflicting reports (★) | +6: 3 other pathogenic changes within 3 positions; A214G at the same position is pathogenic; REVEL 0.788 |
| SLC22A5 W14C | 14 | Cytoplasmic | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; W14R at the same position is pathogenic; REVEL 0.789 |
| SLC22A5 N32H | 32 | Transmembrane | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; N32D at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.65 |
| SLC22A5 Y358S | 358 | Transmembrane | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; Y358N at the same position is pathogenic; REVEL 0.910 |
| SLC22A5 M205K | 205 | Transmembrane | Uncertain | +6: 3 other pathogenic changes within 3 positions; M205R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.93 |
Which prediction tools work for Carnitine deficiency
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- CATVariant: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 99 out of 100
- SIFT: 99 out of 100
- AlphaMissense: 99 out of 100
- MetaLR: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 97 out of 100
- phyloP: 92 out of 100
- MutPred: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 53 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 45 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Frequently asked questions
Which genes have records linked to Carnitine deficiency?
This view contains 1 analyzed proteins: SLC22A5. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 82 pathogenic or likely pathogenic variants, 292 variants of uncertain significance and 59 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 9 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 499 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center